Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High-risk Neuroblastoma: early-phase trial registry
8 of 10 indexed High-risk Neuroblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 8 currently recruiting · #1,724 of 28,707 conditions by registered trial count
High-risk Neuroblastoma: 10 US clinical trials tracked, 8 recruiting.
High-risk Neuroblastoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Stephan Grupp MD PhD, running 2 of these trials.
Enrollment posture brief
Registry condition high-risk-neuroblastoma
OPEN 8 | RECR 80% | LATE 0 | EARLY 8 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Ablation (80% recruiting · 5 trials)
High-risk Neuroblastoma lists 8 open slots (80% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High-risk Neuroblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High-risk Neuroblastoma is recruiting above its size-band peers.
8 of 10 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates High-risk Neuroblastoma research.
Stephan Grupp MD PhD accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most High-risk Neuroblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 10 trials that report a genuine target (sentinel values excluded). 10 of those (100%) plan for fewer than 100 participants.
-
High-risk Neuroblastoma research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT06057948
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Dana-Farber Cancer Institute
NCT06831552
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Y-mAbs Therapeutics
NCT05130255
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
St. Jude Children's Research Hospital
NCT06480526
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Stephan Grupp MD PhD
NCT05650749
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
NCT06528496
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Roberto Chiarle
NCT06803875
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
Stephan Grupp MD PhD
NCT07007117
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
NCT03794349
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
NCT03786783
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on High-risk Neuroblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High-risk Neuroblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High-risk Neuroblastoma page
10 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 High-risk Neuroblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stephan Grupp MD PhD sponsors the most High-risk Neuroblastoma trials on record, review their full trial history before evaluating a specific study. See Stephan Grupp MD PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High-risk Neuroblastoma condition card totals 10 registered trials; most-linked intervention Sargramostim; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.